November 16, 2005
Diabetes drug cuts repeat heart attacks-study
DALLAS (Reuters) - A diabetes drug sold by Takeda
Pharmaceutical Co. and Eli Lilly and Co. significantly cut the
rate of a second heart attack compared with a placebo in
high-risk patients with type-2 diabetes, a study reported on
The data come from a secondary analysis of a failed trial
of the drug Actos reported in September, which had a more
ambitious main goal of preventing a wider range of
cardiovascular incidents, including death, stroke, and heart
attack in high-risk type-2 diabetics.
scientific meeting show that Actos, also known as pioglitazone,
reduced the risk of repeat heart attacks by 28 percent,
according to researchers who conducted the 2,445-patient study.